MAIA - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Story updates
12:51:58 PM UTC
SquawkNews
Strong pace of patient enrollment supports continued advancement toward regulatory milestonesMost recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLCCHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE…
12:52:28 PM UTC
SquawkNews
MAIA Biotechnology enrolled 65 patients in its pivotal Phase 3 THIO-104 trial for third-line NSCLC and targets over 100 randomized patients by year-end. FDA previously granted Fast Track to ateganosine.Material DetailsContext by AI AnalystThis is a mid-stage execution update on MAIA’s lead asset, s…